HC Wainwright Issues Positive Forecast for Disc Medicine (NASDAQ:IRON) Stock Price

Disc Medicine (NASDAQ:IRON) had its price target upped by HC Wainwright from $120.00 to $127.00 in a report issued on Friday,Benzinga reports. HC Wainwright currently has a buy rating on the stock. HC Wainwright also issued estimates for Disc Medicine’s Q1 2027 earnings at ($1.53) EPS.

Several other research analysts also recently issued reports on the company. BMO Capital Markets upped their price objective on Disc Medicine from $100.00 to $120.00 and gave the company an “outperform” rating in a research note on Monday, October 19th. Jefferies Financial Group reiterated a “buy” rating and set a $149.00 target price on shares of Disc Medicine in a research report on Wednesday, October 21st. Morgan Stanley boosted their target price on shares of Disc Medicine from $90.00 to $92.00 and gave the stock an “overweight” rating in a report on Tuesday, October 20th. Wedbush upped their price target on shares of Disc Medicine from $100.00 to $110.00 and gave the company an “outperform” rating in a research report on Monday, October 19th. Finally, Wells Fargo & Company raised their price target on shares of Disc Medicine from $86.00 to $124.00 and gave the company an “overweight” rating in a research note on Tuesday, October 20th. Eleven equities research analysts have rated the stock with a Buy rating, one has given a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $123.40.

Disc Medicine Price Performance

NASDAQ:IRON traded up $0.44 on Friday, hitting $78.91. The company had a trading volume of 717,525 shares, compared to its average volume of 1,553,250. The stock has a market capitalization of $3.03 billion, a price-to-earnings ratio of -12.45 and a beta of 0.96. The company has a current ratio of 24.14, a quick ratio of 24.14 and a debt-to-equity ratio of 0.09. The firm has a 50 day moving average of $71.21 and a two-hundred day moving average of $70.93. Disc Medicine has a 52 week low of $40.00 and a 52 week high of $99.50.

Disc Medicine (NASDAQ:IRON) last issued its earnings results on Thursday, November 5th. The company reported ($1.53) earnings per share for the quarter, beating analysts’ consensus estimates of ($1.63) by $0.10. On average, research analysts anticipate that Disc Medicine will post -6.61 earnings per share for the current year.

Insider Activity

In other Disc Medicine news, CEO John Quisel sold 33,000 shares of the stock in a transaction dated Monday, August 17th. The stock was sold at an average price of $79.15, for a total transaction of $2,611,950.00. Following the completion of the sale, the chief executive officer directly owned 226,064 shares in the company, valued at approximately $17,892,965.60. This trade represents a 12.74% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is accessible through this link. Also, COO Jonathan Yu sold 8,796 shares of Disc Medicine stock in a transaction dated Tuesday, August 25th. The stock was sold at an average price of $83.12, for a total value of $731,123.52. Following the completion of the transaction, the chief operating officer directly owned 54,324 shares of the company’s stock, valued at approximately $4,515,410.88. This trade represents a 13.94% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last three months, insiders have sold 168,046 shares of company stock valued at $13,191,034. 3.76% of the stock is currently owned by insiders.

Institutional Trading of Disc Medicine

Several large investors have recently modified their holdings of IRON. State of Wyoming bought a new stake in shares of Disc Medicine in the 2nd quarter valued at $25,000. Allworth Financial LP acquired a new stake in Disc Medicine in the second quarter worth $46,000. Sterling Capital Management LLC grew its holdings in Disc Medicine by 842.4% in the third quarter. Sterling Capital Management LLC now owns 933 shares of the company’s stock worth $61,000 after purchasing an additional 834 shares during the period. Nykredit A S acquired a new stake in Disc Medicine in the second quarter worth $103,000. Finally, Pinnacle Wealth Planning Services Inc. bought a new stake in Disc Medicine in the third quarter valued at $119,000. Institutional investors and hedge funds own 83.70% of the company’s stock.

About Disc Medicine

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biopharmaceutical company focused on developing treatments for serious hematologic diseases. Its research is centered on the biology of red blood cell production and iron homeostasis, with the goal of addressing disorders in which abnormal iron regulation or ineffective erythropoiesis contributes to disease.

The company’s pipeline includes bitopertin, an investigational oral therapy designed to enhance red blood cell production through inhibition of glycine transporter 1.